Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial

  1. teshima, takanori ORCID logo
  2. Onishi, Yasushi
  3. Kato, Koji
  4. Taniguchi, Shuichi
  5. Miyamura, Koichi
  6. Fukushima, Kentaro
  7. Kato, Jun
  8. Ishikawa, Takayuki
  9. Doki, Noriko
  10. Nakamae, Hirohisa
  11. Maeda, Yoshinobu
  12. Inamoto, Yoshihiro
  13. Okada, Masaya
  14. Maki, Akio
  15. Shimada, Fumika
  16. Tajima, Takeshi
  17. Wroclawska, Monika
  18. Zeiser, Robert
  19. Onizuka, Makoto

Download
12185_2024_Article_3772.pdf 1,11MB
WeightNameValue
1000 Titel
  • Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
1000 Autor/in
  1. teshima, takanori |
  2. Onishi, Yasushi |
  3. Kato, Koji |
  4. Taniguchi, Shuichi |
  5. Miyamura, Koichi |
  6. Fukushima, Kentaro |
  7. Kato, Jun |
  8. Ishikawa, Takayuki |
  9. Doki, Noriko |
  10. Nakamae, Hirohisa |
  11. Maeda, Yoshinobu |
  12. Inamoto, Yoshihiro |
  13. Okada, Masaya |
  14. Maki, Akio |
  15. Shimada, Fumika |
  16. Tajima, Takeshi |
  17. Wroclawska, Monika |
  18. Zeiser, Robert |
  19. Onizuka, Makoto |
1000 Verlag
  • Springer Nature Singapore
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-05-25
1000 Erschienen in
1000 Quellenangabe
  • 120(1):106-116
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s12185-024-03772-6 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11226530/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Acute graft-versus-host disease (aGvHD) is a major complication after allogeneic hematopoietic stem cell transplantation in Japan and other countries. Nearly one-third of patients do not respond to standard systemic steroid therapy and no standard second-line treatment has been established in Japan. We report efficacy and safety findings of ruxolitinib versus best available therapy (BAT) from a subgroup analysis of the international, phase 3 REACH2 study in Japanese patients with steroid-refractory aGvHD. The primary endpoint was overall response rate (ORR) at day 28. Overall, 9 patients received ruxolitinib and 21 received BAT. The ORR at day 28 (88.9% vs 52.4%) and durable ORR at day 56 (66.7% vs 28.6%) were higher with ruxolitinib versus BAT. The estimated cumulative incidence of loss of response at 6 months was 12.5% with ruxolitinib and 18.2% with BAT. The median failure-free survival was longer with ruxolitinib versus BAT (2.73 vs 1.25 months). The most common adverse events up to day 28 in the ruxolitinib and BAT groups were anemia (55.6% vs 19.0%) and thrombocytopenia (44.4% vs 4.8%, respectively). Ruxolitinib showed better efficacy outcomes and a consistent safety profile compared with BAT in the Japanese subgroup, and the findings were consistent with overall study results.</jats:p>
1000 Sacherschließung
lokal Pyrazoles/adverse effects [MeSH]
lokal Aged [MeSH]
lokal Pyrazoles/therapeutic use [MeSH]
lokal Original Article
lokal Acute Disease [MeSH]
lokal Male [MeSH]
lokal JAK inhibitor
lokal East Asian People [MeSH]
lokal Japan [MeSH]
lokal Graft vs Host Disease/drug therapy [MeSH]
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Japanese
lokal Steroids/therapeutic use [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal Hematopoietic Stem Cell Transplantation [MeSH]
lokal Middle Aged [MeSH]
lokal Acute graft-versus-host disease
lokal Nitriles [MeSH]
lokal Pyrimidines/therapeutic use [MeSH]
lokal Young Adult [MeSH]
lokal Graft vs Host Disease/etiology [MeSH]
lokal Ruxolitinib
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-0941-271X|https://frl.publisso.de/adhoc/uri/T25pc2hpLCBZYXN1c2hp|https://frl.publisso.de/adhoc/uri/S2F0bywgS29qaQ==|https://frl.publisso.de/adhoc/uri/VGFuaWd1Y2hpLCBTaHVpY2hp|https://frl.publisso.de/adhoc/uri/TWl5YW11cmEsIEtvaWNoaQ==|https://frl.publisso.de/adhoc/uri/RnVrdXNoaW1hLCBLZW50YXJv|https://frl.publisso.de/adhoc/uri/S2F0bywgSnVu|https://frl.publisso.de/adhoc/uri/SXNoaWthd2EsIFRha2F5dWtp|https://frl.publisso.de/adhoc/uri/RG9raSwgTm9yaWtv|https://frl.publisso.de/adhoc/uri/TmFrYW1hZSwgSGlyb2hpc2E=|https://frl.publisso.de/adhoc/uri/TWFlZGEsIFlvc2hpbm9idQ==|https://frl.publisso.de/adhoc/uri/SW5hbW90bywgWW9zaGloaXJv|https://frl.publisso.de/adhoc/uri/T2thZGEsIE1hc2F5YQ==|https://frl.publisso.de/adhoc/uri/TWFraSwgQWtpbw==|https://frl.publisso.de/adhoc/uri/U2hpbWFkYSwgRnVtaWth|https://frl.publisso.de/adhoc/uri/VGFqaW1hLCBUYWtlc2hp|https://frl.publisso.de/adhoc/uri/V3JvY2xhd3NrYSwgTW9uaWth|https://frl.publisso.de/adhoc/uri/WmVpc2VyLCBSb2JlcnQ=|https://frl.publisso.de/adhoc/uri/T25penVrYSwgTWFrb3Rv
1000 Hinweis
  • DeepGreen-ID: 9ef09e64c78a4dbe8b0021cd732d42fe ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Novartis |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Novartis |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6524784.rdf
1000 Erstellt am 2025-07-07T06:41:24.713+0200
1000 Erstellt von 322
1000 beschreibt frl:6524784
1000 Zuletzt bearbeitet 2025-07-30T14:25:05.257+0200
1000 Objekt bearb. Wed Jul 30 14:25:05 CEST 2025
1000 Vgl. frl:6524784
1000 Oai Id
  1. oai:frl.publisso.de:frl:6524784 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source